Effect of Captopril on Progression to Clinical Proteinuria in Patients With Insulin-Dependent Diabetes Mellitus and Microalbuminuria

Giancarlo Viberti, Carl Erik Mogensen, Leif C. Groop, John F. Pauls, G. Boner, D. J. Van Dyk, A. Lucas, R. Romero, I. Salinas, A. Sanmarti, A. C. Blomqvist, A. Ekstrand, V. L. Kirsi, V. A. Koivisto, Leif C. Groop, P. H. Groop, F. Escobar, F. E. Jimenez, M. M. Campos Pastor, M. MuñozM. Gomez, R. Mangili, G. Pozza, D. Spotti, K. Wurgler Hansen, J. Sandahl Christiansen, F. Klein, C. E. Mogensen, L. G. Van Doorn, P. F M J Spooren, J. K. Cruickshank, J. Jervell, P. N. Paus, A. Collins, G. Viberti, G. Williams, G. A. Nelstrop

Research output: Contribution to journalArticlepeer-review

Abstract

To study the effect of angiotensin converting enzyme inhibition on the rate of progression to clinical proteinuria and the rate of change of albumin excretion rates in patients with insulin-dependent diabetes mellitus and persistent microalbuminuria. —Randomized, double-blind, placebo-controlled clinical trial of 2 years' duration at 12 hospital-based diabetes centers. —Ninety-two patients with insulin-dependent diabetes mellitus and persistent microalbuminuria but no hypertension. —The patients were randomly allocated in blocks of two to receive either captopril, 50 mg, or placebo twice per day. —Albumin excretion rate, blood pressure, glycosylated hemoglobin level, and fructosamine level every 3 months; urinary urea nitrogen excretion every 6 months; and glomerular filtration rate every 12 months. —Twelve patients receiving placebo and four receiving captopril progressed to clinical proteinuria, defined as an albumin excretion rate persistently greater than 200 μg/min and at least a 30% increase from baseline (P=.05). The probability of progression to clinical proteinuria was significantly reduced by captopril therapy (P=.03 by log-rank test). Albumin excretion rate rose from a geometric mean (95% confidence interval) of 52 (39 to 68) to 76 (47 to 122) μg/min in the placebo group but fell from 52 (41 to 65) to 41 (28 to 60) μg/min in the captopril group, a significant difference (P

Original languageEnglish
Pages (from-to)275-279
Number of pages5
JournalJournal of the American Medical Association
Volume271
Issue number4
DOIs
Publication statusPublished - Jan 26 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Effect of Captopril on Progression to Clinical Proteinuria in Patients With Insulin-Dependent Diabetes Mellitus and Microalbuminuria'. Together they form a unique fingerprint.

Cite this